Abstract: Objective To evaluate the recent efficacy and safety of irinotecan（CPT-11） plus raltitrexed as secondline regimen for advanced gastric cancer. Methods Thirty-three patients with advanced gastric cancer were treated with CPT-11（200 mg／m2， 90 min， iv， d1） combined with raltitrexed（3 mg／m2， 15 min， iv， d1） regimen as secondline chemotherapy. Three weeks was a cycle. Response to chemotherapy was assessed by RECIST criteria 1.1 and toxicity was evaluated according to National Cancer Institute Common Toxicity Criteria 4.0. The clinical follow-up data from chemotherapy were investigated. Results Thirty-three patients were all evaluable for recent efficacy and safety. There were no CR， 5 patients of PR， 16 patients of SD， and 12 patients of PD with the response rate of 15.2％ and the disease control rate of 63.6％.The median progressionfree survival was 3.3 months. The most common adverse reactions were anemia， nausea， vomiting， leucopenia， dysfunction of liver， delayed diarrhea， thrombocytopenia and constipation， mainly in grade 1-2. Conclusion CPT-11 combined with raltitrexed is an effective and well-tolerated chemotherapy regimen as second-line treatment for advanced gastric cancer.